RASAL2 and ovarian carcinoma: Because down-regulation of RASAL2 occurs during ovarian cancer, restoring RASAL2 expression or synthesizing a small molecule that can replace RASAL2 and recover the hydrolysis of GTP by Ras may become a novel approach to cancer therapies.